Strategic Collaborations Recent collaboration with Evogene and LMU Munich signals openness to joint development and data-sharing, creating opportunities to co-develop neutrophil-driven inflammatory therapies and related biomarker programs.

Unique Technology Edge Proprietary barcoding technology paired with AI-supported data generation enables rapid target identification, patient stratification, and biomarker discovery, offering scalable services to pharma and gene therapy developers needing high-quality mechanistic data.

Target Market Expansion A focus on neutrophil-derived inflammatory diseases positions Systasy for partnerships seeking precision therapies, with potential to provide pathway screens and patient-derived model analyses to accelerate preclinical programs.

Data-Driven Services The AI-enabled platform creates recurring opportunities for biomarker discovery, patient stratification, and data analytics, enabling upsell of assays, data packages, and model development to support clinical trial design.

EU Growth Potential Germany-based presence and EU collaboration networks offer access to European clinical and regulatory ecosystems, enabling expansion through CRO-like services, joint ventures, and regional partnerships.